BR9811012A - "uso de um composto". - Google Patents

"uso de um composto".

Info

Publication number
BR9811012A
BR9811012A BR9811012-8A BR9811012A BR9811012A BR 9811012 A BR9811012 A BR 9811012A BR 9811012 A BR9811012 A BR 9811012A BR 9811012 A BR9811012 A BR 9811012A
Authority
BR
Brazil
Prior art keywords
compound
steriod
angiostatic
disclosed
methods
Prior art date
Application number
BR9811012-8A
Other languages
English (en)
Inventor
Abbot F Clark
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of BR9811012A publication Critical patent/BR9811012A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE UM COMPOSTO". São apresentados processos para tratamento da neovascularização ocular usando a terapia fotodinâmica, em combinação com um esteróide angiostático.
BR9811012-8A 1997-07-16 1998-06-18 "uso de um composto". BR9811012A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/895,184 US5770592A (en) 1991-11-22 1997-07-16 Prevention and treatment of ocular neovascularization using angiostatic steroids
PCT/US1998/012711 WO1999003503A1 (en) 1997-07-16 1998-06-18 The use of angiostatic steroids in photodynamic therapy

Publications (1)

Publication Number Publication Date
BR9811012A true BR9811012A (pt) 2000-10-17

Family

ID=25404127

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811012-8A BR9811012A (pt) 1997-07-16 1998-06-18 "uso de um composto".

Country Status (13)

Country Link
US (2) US5770592A (pt)
EP (1) EP1003553B1 (pt)
JP (1) JP2001510170A (pt)
AT (1) ATE274356T1 (pt)
AU (1) AU734195B2 (pt)
BR (1) BR9811012A (pt)
CA (1) CA2296558A1 (pt)
DE (1) DE69825906T2 (pt)
DK (1) DK1003553T3 (pt)
ES (1) ES2224412T3 (pt)
HK (1) HK1028952A1 (pt)
PT (1) PT1003553E (pt)
WO (1) WO1999003503A1 (pt)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040089A1 (en) * 1999-01-05 2000-07-13 Massachusetts Eye And Ear Infirmary Targeted transscleral controlled release drug delivery to the retina and choroid
EP1131099A2 (en) 1999-01-15 2001-09-12 Light Sciences Corporation Noninvasive vascular therapy
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
AU2504900A (en) * 1999-01-15 2000-08-01 Light Sciences Corporation Therapeutic compositions for metabolic bone disorders or bone metastases
MXPA02002338A (es) 1999-10-21 2002-07-30 Alcon Universal Ltd Dispositivo para la entrega de drogas.
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
PT1221918E (pt) 1999-10-21 2005-06-30 Alcon Inc Administracao de drogas sub-tenon
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
DE60135633D1 (de) 2000-02-10 2008-10-16 Massachusetts Eye & Ear Infirm Photodynamische therapie zur behandlung von augenerkrankungen
EP1570859A3 (en) * 2000-03-24 2008-04-02 Novartis AG Improved treatment of neovascularization
EP1265636A2 (en) 2000-03-24 2002-12-18 Novartis AG Improved treatment of neovascularization
US8679089B2 (en) 2001-05-21 2014-03-25 Michael S. Berlin Glaucoma surgery methods and systems
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
WO2001089437A2 (en) * 2000-05-19 2001-11-29 Berlin Michael S Laser delivery system and method of use for the eye
JP2004536631A (ja) 2001-05-03 2004-12-09 マサチューセッツ・アイ・アンド・イア・インファーマリー 移植可能な薬物送達デバイスおよびその使用
AU2002319596B2 (en) 2001-07-23 2006-04-27 Alcon, Inc. Ophthalmic drug delivery device
ATE339170T1 (de) * 2001-07-23 2006-10-15 Alcon Inc Vorrichtung zur freisetzung eines ophthalmischen arzneimittels
US7402577B2 (en) * 2001-10-03 2008-07-22 Merck & Co., Inc. Androstane 17-beta-carboxamides as androgen receptor modulators
MXPA04004363A (es) * 2001-11-09 2005-05-16 Eyetech Pharmaceuticals Procedimientos para tratar enfermedades neovasculares oculares.
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
JP4468810B2 (ja) 2002-07-24 2010-05-26 キューエルティー インコーポレーティッド ピラゾリルベンゾチアゾール誘導体および治療薬としてのそれらの使用法
AU2003259301A1 (en) * 2002-07-29 2004-02-16 Ast Products, Inc. Ophtalmic compositions
US6828356B2 (en) * 2002-07-29 2004-12-07 Ast Products, Inc. Preparation of ophthalmic compositions
US6806364B2 (en) * 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
JP2005535691A (ja) * 2002-08-05 2005-11-24 アルコン，インコーポレイテッド 加齢性黄斑変性を有する患者における視力の保護のための酢酸アネコルタブの使用
DE10238310A1 (de) * 2002-08-21 2004-03-04 Erich Jaeger Gmbh Elektrodenanordnung
AU2003299201A1 (en) * 2002-10-03 2004-04-23 Light Sciences Corporation Excitation of photoreactive compounds in eye tissue
US20060167435A1 (en) * 2003-02-18 2006-07-27 Adamis Anthony P Transscleral drug delivery device and related methods
CN1750828A (zh) * 2003-02-20 2006-03-22 爱尔康公司 类固醇治疗眼病患者的用途
US20060074061A1 (en) * 2003-02-20 2006-04-06 Bingaman David P Formulations of glucocorticoids to treat pathologic ocular angiogenesis
US20070043006A1 (en) * 2003-06-13 2007-02-22 Bingaman David P Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
EP1635842A4 (en) * 2003-06-20 2007-04-04 Alcon Inc TREATMENT OF AMD WITH A COMBINATION OF INGREDIENTS
KR20060082792A (ko) * 2003-07-10 2006-07-19 알콘, 인코퍼레이티드 안과용 약물 전달 장치
CN1882338A (zh) * 2003-09-18 2006-12-20 马库赛特公司 经巩膜递送
JP2007506678A (ja) * 2003-09-23 2007-03-22 アルコン，インコーポレイテッド 注入のためのトリアムシノロンアセトアニドおよび酢酸アネコルタブの処方物
WO2005072744A1 (ja) * 2004-02-02 2005-08-11 Yuichi Kaji 硝子体の可視化剤
EP1720874A4 (en) * 2004-02-24 2010-03-03 Bioaxone Therapeutique Inc SUBSTITUTED PIPERIDINE DERIVATIVES IN POSITION 4
US20050239760A1 (en) * 2004-04-23 2005-10-27 Alcon, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
ATE515288T1 (de) 2004-09-24 2011-07-15 Rfe Pharma Llc Carboxy-amido-triazole zur lokalisierten behandlung von augenerkrankungen
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
ES2675878T3 (es) 2005-05-25 2018-07-13 Cis Pharma Ag Polímeros y copolímeros biocompatibles que comprenden aminoácidos en la cadena lateral
PT1919290E (pt) * 2005-07-12 2014-03-20 Ampio Pharmaceuticals Inc Métodos e produtos para tratamento de doenças
CN101267779A (zh) 2005-07-27 2008-09-17 福罗里达大学研究基金会有限公司 使用热休克治疗眼睛疾病
KR101390127B1 (ko) 2005-09-07 2014-05-13 암젠 프레몬트 인코포레이티드 액티빈 수용체 유사 키나제-1에 대한 인간 모노클로날 항체
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
WO2007047626A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis
AU2006304553A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Method for treating primary and secondary forms of glaucoma
US20080125406A1 (en) * 2005-10-14 2008-05-29 Robin Alan L Method for Treating Primary and Secondary Forms of Glaucoma
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
BRPI0619057A2 (pt) 2005-11-29 2011-09-20 Smithkline Beecham Corp formulação farmacêutica de uso tópico, uso de um ou mais compostos, e, compostos
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
KR101520408B1 (ko) 2006-03-23 2015-05-14 산텐 세이야꾸 가부시키가이샤 혈관 투과성-관련 질환 또는 상태를 위한 제형 및 방법
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
US20090181933A1 (en) * 2008-01-11 2009-07-16 Bingaman David P Use of steroids to treat persons suffering from ocular disorders
CN101965211A (zh) 2008-03-05 2011-02-02 伊万提斯公司 治疗青光眼的方法和装置
EP2805720B1 (en) * 2008-05-28 2019-08-07 ReveraGen BioPharma, Inc. Non-hormonal steroid modulators of NF-KB for treatment of disease
US8372036B2 (en) 2009-05-06 2013-02-12 Alcon Research, Ltd. Multi-layer heat assembly for a drug delivery device
IN2012DN00352A (pt) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
HUE028212T2 (en) 2009-06-22 2016-12-28 Ampio Pharmaceuticals Inc Procedure for treating diseases
MX2011013984A (es) * 2009-06-22 2012-06-01 Dmi Acquisition Corp Metodos y productos para el tratamiento de enfermedades.
EP2451375B1 (en) 2009-07-09 2018-10-03 Ivantis, Inc. Single operator device for delivering an ocular implant
AU2010271218B2 (en) 2009-07-09 2017-02-02 Alcon Inc. Ocular implants and methods for delivering ocular implants into the eye
US20120232102A1 (en) 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
US9198921B2 (en) 2010-04-05 2015-12-01 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
US20120283557A1 (en) 2011-05-05 2012-11-08 Berlin Michael S Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses
CA2838974A1 (en) 2011-06-14 2012-12-20 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
US9499464B2 (en) 2011-10-19 2016-11-22 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
JP6126118B2 (ja) 2011-11-30 2017-05-10 ビカム ファーマスーティカルス，インコーポレイテッド オプシン結合性リガンド、組成物、及び使用方法
BR112014013106A2 (pt) 2011-12-01 2017-06-13 Bikam Pharmaceuticals Inc ligantes de ligação à opsina, composições e métodos de uso
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
WO2014085450A1 (en) 2012-11-28 2014-06-05 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
EA201500752A1 (ru) 2012-12-19 2016-05-31 Ампио Фармасьютикалс, Инк. Способ лечения заболеваний
WO2016011056A1 (en) 2014-07-14 2016-01-21 Ivantis, Inc. Ocular implant delivery system and method
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
CN108135470B (zh) 2015-08-14 2021-03-09 伊万提斯公司 具有压力传感器和输送系统的眼部植入物
US11938058B2 (en) 2015-12-15 2024-03-26 Alcon Inc. Ocular implant and delivery system
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
WO2019014322A1 (en) 2017-07-11 2019-01-17 BioAxone BioSciences, Inc. KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
WO2019164834A1 (en) 2018-02-22 2019-08-29 Ivantis, Inc. Ocular implant and delivery system
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
KR20230130622A (ko) 2021-01-11 2023-09-12 알콘 인코포레이티드 점탄성 전달을 위한 시스템 및 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
ATE190623T1 (de) * 1990-06-11 2000-04-15 Alcon Lab Inc Verwendung von steroiden zur inhibierung von angiogenesis
WO1995024930A1 (en) 1994-03-14 1995-09-21 Massachusetts Eye & Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy

Also Published As

Publication number Publication date
HK1028952A1 (en) 2001-03-16
EP1003553A1 (en) 2000-05-31
DE69825906D1 (de) 2004-09-30
AU8151598A (en) 1999-02-10
DE69825906T2 (de) 2005-09-01
DK1003553T3 (da) 2004-09-20
JP2001510170A (ja) 2001-07-31
EP1003553B1 (en) 2004-08-25
ES2224412T3 (es) 2005-03-01
CA2296558A1 (en) 1999-01-28
AU734195B2 (en) 2001-06-07
WO1999003503A1 (en) 1999-01-28
US6297228B1 (en) 2001-10-02
US5770592A (en) 1998-06-23
ATE274356T1 (de) 2004-09-15
PT1003553E (pt) 2004-10-29

Similar Documents

Publication Publication Date Title
BR9811012A (pt) "uso de um composto".
HK1029922A1 (en) Angiostatic agents and compositions for treating glc1a glaucoma
DK0841949T3 (da) Anvendelse af saccharid-konjugater
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
TR199801195T2 (xx) Tedavide yararl� kinolin ve kinozilin bile�ikleri.
PT927150E (pt) Compostos de lipoxina e sua utilizacao no tratamento de doencas proliferativas celulares
HUP0000576A2 (hu) A zöld porfirinek alkalmazása szekunder szürkehályogok kezelésére alkalmas gyógyszerek készítésében
DK0664708T3 (da) Metode til behandling af cancer ved kombinationsbehandling med 2'-halogenmethylidenderivater og et S-fase- eller M-fase-spe
UA41355C2 (uk) Засіб для лікування нейро-сніду
NO954878L (no) Pyrrolderivater
TR199901104T2 (xx) Farmas�tik bile�ikler.
DK0837935T3 (da) Den 3'-ikke-translaterede region af det humane prohibitin-gen
DE69705421D1 (de) 15-fluoro-prostaglandine als augendrucksenkende mittel
DE69710333D1 (de) Cyclopentan(en)säure-2-alkenyl-derivate als therapeutika in der behandlung der okulären hypertonie
PT1131073E (pt) Uso de derivados de estaurosporina para o tratamento de doencas oculares neovasculares
PL339073A1 (en) Derivatives of benzoxazine and benzothiazine and their application in therapeutic agents
IL131478A0 (en) Methods for treatment of scar tissue
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
BR0015938A (pt) Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa
DK0458587T3 (da) Behandling af okulær hypertension med en synergistisk kombination til ophthalmisk anvendelse
DK0850062T3 (da) Anvendelse af halofuginon til fremstilling af et medikament til svækkelse af neovaskularisering og til behandling af maligne tumorer hos mennesker
AU7985698A (en) Methods for treatment of ocular neovascularization
ITRM930154A0 (it) Uso di terbinafina per il trattamento terapeutico della pneumocistosi.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: ALCON MANUFACTURING, LTD. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM ART. 13 DA LPI )